Clinical Trials

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07479979 2026-03-18

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT05583617 2026-03-06

PLYCOM

200 enrolled

Multiple Myeloma

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

52 enrolled

Multiple Myeloma

NCT05434689 2026-03-05

COMMANDER

80 enrolled

Multiple Myeloma

NCT06232044 2026-03-04

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Suspended

88 enrolled

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT00378105 2026-02-24

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

68 enrolled 9 charts

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

17 enrolled

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

66 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT06988488 2026-02-02

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT03215030 2026-01-29

iinnovate-1

272 enrolled 67 charts

Multiple Myeloma

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

49 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06645678 2025-12-03

MELT-MM

75 enrolled

Multiple Myeloma

NCT05392946 2025-10-29

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

49 enrolled

Phase 1/2 Enrolling by invitation

Multiple Myeloma

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

21 enrolled

Multiple Myeloma

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

37 enrolled

Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

14 enrolled

Multiple Myeloma

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

87 enrolled 13 charts

Amyloidosis, Multiple Myeloma

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

53 enrolled

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT06087653 2025-06-19

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

24 enrolled

Multiple Myeloma

NCT04896658 2025-04-03

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

10 enrolled 14 charts

Multiple Myeloma

NCT02649790 2025-03-19

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

GastrointestinalMyeloidOther hematologic neoplasmPlasma cell

277 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03544281 2025-03-18

DREAMM 6

153 enrolled 91 charts

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

103 enrolled

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

14 enrolled

Multiple Myeloma, Recurrence

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02542657 2024-09-19

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

30 enrolled

Neoplasms, Plasma Cell

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

33 enrolled 26 charts

Chromosome 17 deletion, Multiple Myeloma

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

17 enrolled 10 charts

Multiple Myeloma

NCT02773030 2024-06-25

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

466 enrolled

Multiple Myeloma, Recurrence

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

42 enrolled

Multiple Myeloma

NCT02119468 2024-03-15

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

32 enrolled 15 charts

Multiple Myeloma

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT05647512 2023-11-18

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

108 enrolled

Amyloidosis, Multiple Myeloma

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

36 enrolled

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

56 enrolled 38 charts

Multiple Myeloma

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

11 enrolled 11 charts

Multiple Myeloma

NCT02204241 2023-07-03

CCD

36 enrolled